Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Home
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • Use of lithium and cancer risk in patients with bipolar disorder: population-based cohort study
  • Ru-Yu Huang, Kun-Pin Hsieh, Wan-Wen Huang, Yi-Hsin Yang
  • Journal: The British Journal of Psychiatry / Volume 209 / Issue 5 / November 2016
  • Published online by Cambridge University Press: 02 January 2018, pp. 393-399
  • Print publication: November 2016
    • Article
      • You have access
    • PDF
    • HTML
    • Export citation
  • View abstract
    Background

    Lithium inhibits glycogen synthase kinase-3, which is an enzyme involved in the pathogenesis of cancer.

    Aims

    To investigate the association between lithium and cancer risk in patients with bipolar disorder.

    Method

    A retrospective cohort study was designed using the National Health Insurance Research Database (NHIRD) in Taiwan. Patients using lithium comprised the index drug group and patients using anticonvulsants only comprised the control group. Time-dependent Cox regression was used to evaluate the hazard ratios (HRs) for risk of cancer.

    Results

    Compared with anticonvulsant-only exposure, lithium exposure was associated with significantly lower cancer risk (HR = 0.735, 95% CI 0.554–0.974). The hazard ratios for the first, second and third tertiles of the cumulative defined daily dose were 0.762 (95% CI 0.516–1.125), 0.919 (95% CI 0.640–1.318) and 0.552 (95% CI 0.367–0.831), respectively.

    Conclusions

    Lithium is associated with reduced overall cancer risk in patients with bipolar disorder. A dose–response relationship for cancer risk reduction was observed.